Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Dicerna Pharmaceutic (DRNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 673,720
  • Shares Outstanding, K 62,732
  • Annual Sales, $ 2,280 K
  • Annual Income, $ -60,050 K
  • 36-Month Beta 2.23
  • Price/Sales 71.61
  • Price/Cash Flow N/A
  • Price/Book 4.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.23
  • Number of Estimates 5
  • High Estimate -0.11
  • Low Estimate -0.37
  • Prior Year -0.90
  • Growth Rate Est. (year over year) +74.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.39 +14.38%
on 01/29/19
12.08 -11.09%
on 01/22/19
-0.03 (-0.28%)
since 01/18/19
3-Month
9.31 +15.36%
on 12/24/18
15.21 -29.39%
on 12/03/18
-3.23 (-23.12%)
since 11/21/18
52-Week
8.71 +23.31%
on 04/02/18
17.98 -40.27%
on 09/14/18
-0.76 (-6.61%)
since 02/21/18

Most Recent Stories

More News
ADDING MULTIMEDIA Dicerna Bolsters Leadership Team to Support Continued Growth

---- Rebecca Peterson Hired as Head of Corporate Communications --

DRNA : 10.74 (+2.97%)
Dicerna Bolsters Leadership Team to Support Continued Growth

---- Rebecca Peterson Hired as Head of Corporate Communications --

DRNA : 10.74 (+2.97%)
Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer

Skyhawk signals progression toward the clinical stage with the hire of CMO Dr. Roberto Guerciolini, M.D., who brings deep experience as a clinician who took several of the earliest RNA targeting drugs...

DRNA : 10.74 (+2.97%)
WVE : 36.98 (-0.27%)
Recent Analysis Shows DICK'S Sporting Goods, Zix, Q2, InfraREIT, The Boston Beer, and Dicerna Pharmaceuticals Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of DICK'S Sporting Goods, Inc....

DRNA : 10.74 (+2.97%)
ZIXI : 8.60 (+2.14%)
HIFR : 21.27 (unch)
DKS : 37.87 (-0.79%)
QTWO : 66.26 (+1.41%)
SAM : 306.75 (+14.33%)
Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee...

DRNA : 10.74 (+2.97%)
Dicerna Announces Dosing of First Volunteer in Phase 1 Clinical Trial of DCR-HBVS Designed for the Treatment of Chronic Hepatitis B Virus

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), (the "Company") a leading developer of RNA interference (RNAi) therapeutics, today announced the dosing of the first human volunteer in...

DRNA : 10.74 (+2.97%)
Dicerna Evolves Its Board of Directors to Support Continued Growth

---- Company Thanks Departing Chairman David Madden and Director Brian Halak --

DRNA : 10.74 (+2.97%)
Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), (the "Company"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that on January 2, 2019,...

DRNA : 10.74 (+2.97%)
Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna

Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Boehringer...

DRNA : 10.74 (+2.97%)
Dicerna to Join NASDAQ Biotechnology Index

SOURCE: Dicerna Pharmaceuticals, Inc.

DRNA : 10.74 (+2.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade DRNA with:

Business Summary

Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals,...

See More

Key Turning Points

2nd Resistance Point 11.16
1st Resistance Point 10.95
Last Price 10.74
1st Support Level 10.34
2nd Support Level 9.94

See More

52-Week High 17.98
Fibonacci 61.8% 14.44
Fibonacci 50% 13.34
Fibonacci 38.2% 12.25
Last Price 10.74
52-Week Low 8.71

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar